Hims & Hers Acquires Honest Health to Expand UK Footprint

Hims & Hers Acquires Apostrophe

June 24, 2021

Healthcare Services

Hims & Hers Health, Inc. completed the acquisition of teledermatology specialist Apostrophe to deepen its personalized dermatology offering and integrate Apostrophe's clinical team and compounding pharmacy capabilities. The entire Apostrophe team will join Hims & Hers, with Apostrophe CEO Ben Holber becoming head of Hims & Hers' dermatology business line.

Hims & Hers Acquires ZAVA

June 3, 2025

Healthcare Services

Hims & Hers Health, Inc. agreed to acquire ZAVA, a leading European digital health and telemedicine platform, in an all-cash transaction to accelerate the company's expansion into the UK and launch operations in Germany, France and Ireland. The acquisition brings ZAVA’s ~1.3 million active customers and nearly 2.3 million consultations in 2024 onto Hims & Hers’ platform and is expected to be accretive by 2026.

Hims & Hers to Go Public via Merger with Oaktree Acquisition Corp.

October 1, 2020

Healthcare Services

Hims & Hers (Hims, Inc.), a multi-specialty telehealth and consumer health platform, entered a definitive merger agreement with SPAC Oaktree Acquisition Corp. The business combination values the combined company at an approximate $1.6 billion enterprise value and provides up to $280 million of cash (including a $75 million PIPE led by Franklin Templeton and certain Oaktree clients) to accelerate Hims & Hers' growth and expansion into new care categories.

Hims & Hers Acquires US-based Peptide Facility in California

February 21, 2025

Pharmaceuticals

Hims & Hers Health, Inc. has acquired a US-based peptide manufacturing facility in California to further verticalize its supply chain and expand domestic capabilities for personalized medications. The acquisition, which closed in early February, strengthens Hims & Hers’ ability to meet growing consumer demand for personalized healthcare and peptide-based treatments.

Hims & Hers Acquires MedisourceRx from Nivagen Pharmaceuticals

September 12, 2024

Pharmaceuticals

Hims & Hers has acquired MedisourceRx, the FDA-registered 503B outsourcing facility and business unit of Nivagen Pharmaceuticals. Bourne Partners served as exclusive financial adviser to Nivagen; proceeds from the sale will allow Nivagen to complete a sterile injectables facility in California and advance its pipeline.

Herspiegel Acquires U.K.-based Decisive Consulting

June 23, 2025

Healthcare Services

Herspiegel, a pharmaceutical commercialization consultancy and portfolio company of DFW Capital Partners, has acquired U.K.-based Decisive Consulting to expand its global market access, HEOR and HTA capabilities. Decisive's founder Esther Nzenza will remain in a senior role as the firm is integrated into Herspiegel's global commercialization platform.